Wodak Alex
Expert Opin Drug Saf. 2005 Sep;4(5):815-9. doi: 10.1517/14740338.4.5.815.
Heroin prescription (HP) to treat severe heroin dependence has been available to few patients in the UK for several decades with limited, but generally favourable, evaluation. In the last decade, large trials have been reported from two countries, are presently underway in three other countries and under consideration in several other countries. The standard pharmacological treatments for heroin dependence, methadone and buprenorphine, attract and retain many more drug users than other pharmacological or nonpharmacological treatments and are strongly supported by evidence of efficacy, effectiveness, safety and cost effectiveness. On present evidence, HP is feasible and safe with limited, but increasing, evidence of efficacy and effectiveness. Although HP is more expensive than methadone, there is some evidence of cost effectiveness. HP is, at present, only considered a therapeutic option for a small minority of treatment refractory, severely heroin-dependent persons in developed countries with comprehensive treatment systems.
几十年来,在英国,使用海洛因处方(HP)治疗严重海洛因依赖的患者寥寥无几,相关评估有限但总体较为积极。在过去十年中,已有两个国家报告了大规模试验,另外三个国家正在进行试验,还有几个国家正在考虑开展试验。用于治疗海洛因依赖的标准药物疗法——美沙酮和丁丙诺啡,相较于其他药物或非药物疗法,吸引并留住了更多吸毒者,且有充分的疗效、有效性、安全性及成本效益证据作为有力支撑。根据现有证据,HP是可行且安全的,不过其疗效和有效性的证据有限但在不断增加。尽管HP比美沙酮更昂贵,但也有一些成本效益方面的证据。目前,在拥有综合治疗体系的发达国家,HP仅被视为一小部分治疗难治性、严重海洛因依赖者的治疗选择。